How big is Axsome Therapeutics, Inc.?

As of Jun 18, Axsome Therapeutics, Inc. has a market capitalization of $5.00 billion, with net sales of $432.16 million and a net profit of -$278.26 million over the last four quarters. The company reported shareholder's funds of $57.02 million and total assets of $568.50 million as of Dec 24.

Market Cap: As of Jun 18, Axsome Therapeutics, Inc. has a market capitalization of 5,002.41 million, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Axsome Therapeutics, Inc. reported net sales of 432.16 million and a net profit of -278.26 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 57.02 million and total assets of 568.50 million.

What does Axsome Therapeutics, Inc. do?

Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders. As of March 2025, it reported net sales of $121 million and a net loss of $59 million, with a market cap of approximately $5 billion.

Overview: <BR>Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain, and operates in the Pharmaceuticals & Biotechnology industry within the small-cap market.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 121 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -59 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 5,002.41 Million (Small Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -2.13 <BR>Return on Equity: -464.66% <BR>Price to Book: 94.02<BR><BR>Contact Details: <BR>Address: 22 CORTLANDT STREET, 16TH FLOOR, NEW YORK NY: 10007 <BR>Tel: 1 212 3323241 <BR>Fax: 1 212 3200245 <BR>Website: http://axsome.com/

Should I buy, sell or hold Axsome Therapeutics, Inc.?

Who are in the management team of Axsome Therapeutics, Inc.?

As of March 2022, the management team of Axsome Therapeutics, Inc. includes Dr. Herriot Tabuteau as Chairman, President, and CEO, with Dr. Roger Jeffs as Lead Independent Director, and Dr. Mark Coleman and Mr. Mark Saad as Independent Directors.

As of March 2022, the management team of Axsome Therapeutics, Inc. includes Dr. Herriot Tabuteau, who serves as the Chairman of the Board, President, Chief Executive Officer, and is also the Founder. Additionally, Dr. Roger Jeffs holds the position of Lead Independent Director, while Dr. Mark Coleman and Mr. Mark Saad serve as Independent Directors.

Is Axsome Therapeutics, Inc. overvalued or undervalued?

As of August 9, 2022, Axsome Therapeutics is considered a risky investment due to its high price-to-book value of 103.56 and negative earnings metrics, despite a strong year-to-date return of 40.21%.

As of 9 August 2022, the valuation grade for Axsome Therapeutics, Inc. moved from does not qualify to risky, indicating increased caution regarding its investment potential. The company appears overvalued, particularly given its high price-to-book value of 103.56 and negative earnings metrics, such as an EV to EBITDA ratio of -23.34 and an ROE of -464.66%. In comparison, BioMarin Pharmaceutical, Inc. has a fair valuation with a P/E of 15.17, while BridgeBio Pharma, Inc. is also classified as risky with a P/E of -14.12.<BR><BR>Despite a strong year-to-date return of 40.21% compared to the S&P 500's 12.22%, the overall financial metrics suggest that Axsome Therapeutics is not a sound investment at its current valuation levels.

Is Axsome Therapeutics, Inc. technically bullish or bearish?

As of August 18, 2025, Axsome Therapeutics shows a bullish trend supported by strong technical indicators, outperforming the S&P 500 with a 29.59% annual return compared to 17.14%.

As of 18 August 2025, the technical trend has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The MACD is bullish on both the weekly and monthly time frames, and the moving averages are bullish on the daily. Bollinger Bands show a bullish signal on the weekly and a mildly bullish signal on the monthly. The KST is bullish for both weekly and monthly periods. However, Dow Theory indicates a mildly bearish stance on the weekly while being mildly bullish on the monthly, and the OBV shows a mildly bearish signal on the weekly but mildly bullish on the monthly.<BR><BR>In terms of performance, Axsome Therapeutics has outperformed the S&P 500 over the year with a return of 29.59% compared to the S&P 500's 17.14%, and significantly over the YTD with a return of 40.21% against the S&P 500's 12.22%.